FOLH1 and prostate cancer: As prostate cancer is a heterogenous disease and primary tumor and metastases do not always show concordant PSMA expression, it has been shown that increasing PSMA percentage negativity of the primary tumor on immunohistochemistry is associated with an increasing rate of PSMA negative scans as well as PSMA negative metastases (15).